The Details

The US government has mandated that private health insurance companies must reimburse individuals for purchasing at-home COVID-19 tests. Here are a few things you should know.

Start date
This program applies to purchases made on or after January 15, 2022.

Coverage
This applies only to individuals covered by a private health insurance plan.

Number of tests
Each covered individual is eligible for up to eight at-home COVID-19 tests a month.

Cost
Private insurers are required to reimburse FDA-authorized at-home tests, like On/Go™, up to $12 per individual test.

How do I get reimbursed for On/Go tests I purchased through Ro?

When submitting a claim to your private insurance company for reimbursement, you will likely be required to submit a few pieces of information like proof of purchase and the number of tests ordered. Here’s what you need to do:

  • Visit your insurance company’s website or call their member services phone number to find out how to submit a claim for reimbursement.
  • If you need a detailed receipt for reimbursement, e-mail care@ro.co or call a member of our Customer Care team at 424-347-6299. You’ll have an electronic Ro reimbursement receipt emailed within 24 hours.

Please note

Since this is a new program, the guidelines for reimbursement may vary from one insurance company to another and may change over time. Please consult with your insurance provider about reimbursement options before purchasing.

As of this time, Medicare, Medicare Supplement, and Medicaid don’t reimburse for over-the-counter COVID-19 tests.

The use of your health data and any other data collected through the On/Go app is subject to On/Go’s Privacy Policy and End User License Agreement, which are available through the On/Go app.

This product has not been FDA cleared or approved, but has been authorized by FDA under an EUA. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

The expiration is at the end of the month. For example, February 2022 means the product expires on February 28, 2022.